Gil Blum, an analyst from Needham, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The associated price target remains the same with $81.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gil Blum’s rating is based on several strategic and performance factors related to Crispr Therapeutics AG. The company has aligned the timeline for its CTX320 clinical data with the anticipated HORIZON CVOT readout, which is expected to demonstrate the benefits of Lp(a) reduction in cardiovascular outcomes. This strategic alignment suggests that Crispr is positioning itself to capitalize on potential positive outcomes from the HORIZON study, which could validate Lp(a) as a biomarker in future registrational studies.
Furthermore, the updated results for Crispr’s CTX310 show significant reductions in triglycerides and LDL cholesterol, indicating promising therapeutic potential. These results are consistent with previous reports, reinforcing confidence in the company’s ongoing clinical developments. The strategic decisions and positive clinical data underpin the Buy rating and the $81 price target set by Gil Blum.
According to TipRanks, Blum is an analyst with an average return of -10.5% and a 33.47% success rate. Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Crispr Therapeutics AG, and Autolus Therapeutics.
In another report released on June 18, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target.